To examine the trajectories of anxiety and depression symptoms over the course of oncological disease, and to assess potential predictors-sociodemographic (age, sex, marital status, employment status), clinical (tumor location, stage, treatment type, general health), psychological (coping strategies, quality of life, cognitive difficulties, fear of recurrence), and physical activity-and their association with support needs and utilization of psychosocial services.
The study population consists of consecutive oncology patients recruited across multiple centers, with data collection occurring at baseline (diagnosis or treatment initiation) and at 3-month and 6-month follow-up time points.
Study Type
OBSERVATIONAL
Enrollment
540
Participants complete standardized self-report questionnaires and undergo medical record review at three time points (baseline, 3 months, and 6 months) to assess psychological symptoms (anxiety, depression, somatization), coping strategies, quality of life, cognitive difficulties, physical activity, nutrition, supportive care needs, and informed decision-making in the context of cancer treatment. No experimental treatment or therapy is administered.
Hospital Universitario Marqués de Valdecilla
Santander, Cantabria, Spain
RECRUITINGHospital General Universitario de Ciudad Real
Ciudad Real, Ciudad Real, Spain
RECRUITINGHospital Universitario Virgen de la Luz
Cuenca, Cuenca, Spain
RECRUITINGHospital General Universitario de Elche
Alicante, Elche, Spain
RECRUITINGHospital Universitario del Sureste
Arganda, Madrid, Spain
RECRUITINGHospital Universitario La Paz
Fuencarral-El Pardo, Madrid, Spain
RECRUITINGHospital Universitario Fuenlabrada
Fuenlabrada, Madrid, Spain
RECRUITINGHospital Universitario de La Princesa
Salamanca, Madrid, Spain
RECRUITINGHospital Universitario Infanta Sofía
San Sebastián de los Reyes, Madrid, Spain
RECRUITINGHospital Universitario Infanta Leonor
Vallecas, Madrid, Spain
RECRUITING...and 8 more locations
Anxiety and depression symptoms
The primary outcome of our study is psychological distress, specifically anxiety and depression symptoms, which will be measured using the Brief Symptom Inventory-18 (BSI-18). BSI-18 provides a single outcome measure for distress. The scoring ranges are as follows: 0-66 (low risk of depression and/or anxiety), 67-71 (intermediate risk), and \>71 (clinically significant distress).
Time frame: At the time of diagnosis or treatment initiation. Follow-up at 3 months: To assess the early evolution of symptoms. Follow-up at 6 months: To analyze the medium-term evolution.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.